We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Virus Linked to Aggressive Breast Cancers

By Biotechdaily staff writers
Posted on 21 Jul 2004
Nearly three-quarters of a small sample of Tunisian breast cancer patients showed evidence of a virus similar to one known to cause breast cancer in mice, according to a study published in the July 12, 2004, issue of Cancer.

This is twice the rate seen in women in the United States. More...
Although viruses are known to play a primary role in the development of several human cancers, such as the T cell lymphotropic virus and adult T cell leukemia/lymphoma or herpes virus 8 (HHV8) and Kaposi sarcoma (KS), geographic variability has been noted. For example, KS and HHV8 are least common in the United States and more common in the Mediterranean and Central African regions.

Previous analyses of human breast tissue found viral sequences from the mouse mammary tumor virus (MMTV) in a large percentage of breast cancers but not in normal tissue. MMTV may be spread by a species of house mouse very common in North Africa but not in the United States.

Researchers compared 38 breast tumors from Tunisian patients with samples from several other countries. A significantly higher proportion of samples from Tunisia tested positive for an MMTV-specific genetic sequence, compared to samples from North America. While 74% of Tunisian samples tested positive, other studies reported only 36% from the United States, 38% from Italy, 42% from Australia, and 31% from Argentina. Further analyses revealed that 89% of the MMTV-positive samples were from clinically and histologically aggressive tumors.

"These findings provide increasing evidence for a human breast cancer virus with geographic differences in prevalence,” concluded the authors. The study was conducted by Dr. Paul H. Levine from the George Washington University School of Public Health and Health Services (Washington, DC, USA; www.gwumc.edu) and his colleagues.





Related Links:
George Washington Univ. School of Public Health

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.